In our recent work, we have found that PARG loss is the most frequently detected PARPi-resistance mechanism in mammary tumors from BRCA2-deficient triple-negative breast cancer (TNBC) mouse models (Gogola et al, 2018; Bhin et al, 2023). This evidence concerns the gene PARG and breast cancer.